Calendar
All Topics (February 6 through February 25)
Wednesday, February 6
- 8:00 AM The National Emerging Infectious Diseases Laboratories – An Update from the Acting Director - GIM Grand Rounds
- 2:00 PM Phenotypic screen for Identification of Immunomodulatory Drugs
Thursday, February 7
- 12:00 PM ID Grand Rounds
Friday, February 8
- 9:00 AM Geriatrics Section Education Conference Series
- 12:00 PM Medical Grand Rounds: Language barriers and Medical Interpretation: USA 1984-2013
Tuesday, February 12
- 8:00 AM Clinical Neuroscience Grand Rounds
- 12:00 PM Biochemistry Seminar: David Mangelsdorf, Ph.D. "Nuclear receptors, FGFs and the regulation of nutrient metabolism"
- 3:00 PM Computational Biomedicine Seminar
Wednesday, February 13
- 8:00 AM Faculty Revelations - GIM Grand Rounds
- 12:00 PM CARE Unit Journal Club - A Randomized Trial of Cognitive Behavioral Therapy in Primary Care-based Buprenorphine
- 2:00 PM Pyroglutamate Abeta as an Immunotherapeutic Target for AD
Thursday, February 14
- 12:00 PM ID Grand Rounds: "A New Role for Killer Cells in Bacterial Defense'
- Biochemistry Post Doc/Student Seminar
- 12:30 PM 27 yo woman on methadone who is breastfeeding - CARE Addiction Case conference
Friday, February 15
- 9:00 AM Geriatrics Section Education Conference Series
- 12:00 PM Medical Grand Rounds: The changing Landscape and Challenges of AL Amylodosis
- 1:45 PM “Development of Humanized Mouse Models for Biomedical Research”
Tuesday, February 19
- 12:00 PM Inflammatory cytokines and mortality in a cohort of HIV-infected patients with alcohol problems - Research in Progress
- Biochemistry Seminar: Ileana M. Cristea, Ph.D. "Emerging roles for acetylation in regulating host defense mechanisms against viral infection"
Wednesday, February 20
Thursday, February 21
- 12:00 PM Academy for Faculty Advancement
Friday, February 22
- 9:00 AM Geriatrics Section Education Conference Series
- 12:00 PM Medical Grand Rounds: EBM: Evidence Based Mentorship
- 1:45 PM "Development of Novel TDP-43 Inclusion Inhibitors as Potential ALS/FTLD Therapeutics"
